Additionally, in a separate study of patients with non-Hodgkin lymphoma (NHL) receiving CD19-targeted CAR-T cell therapy, lower pretreatment serum ALB levels were associated with an elevated risk of acute kidney injury (AKI). Here, CD19 is linked to acute kidney injury.